Medindia

X

Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference

Saturday, November 21, 2009 General News J E 4
Advertisement


ST. LOUIS, Nov. 20 Centene Corporation (NYSE: CNC) today announced that it will present at the Bank of America Merrill Lynch 2009 Credit Conference, to be held December 2-3, 2009, at the Crowne Plaza Hotel Times Square in New York City.

Centene will present Wednesday, December 2nd at 8:30 a.m. Eastern Time. Investors and other interested parties may access a live, audio webcast of Centene's presentation at: http://www.veracast.com/webcasts/bas/credit09/id78103522.cfm.

A webcast replay can be accessed shortly after the presentation via the Company's website at www.centene.com under the Investors section.

About Centene Corporation

Centene Corporation is a leading multi-line healthcare enterprise that provides programs and related services to individuals receiving benefits under Medicaid, including the Children's Health Insurance Program (CHIP), as well as Aged, Blind, or Disabled (ABD), Foster Care, Long-Term Care and Medicare (Special Needs Plans). The Company operates local health plans and offers a wide range of health insurance solutions to individuals and the rising number of uninsured Americans. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health, life and health management, managed vision, telehealth services, pharmacy benefits management and medication adherence. Information regarding Centene is available via the Internet at www.centene.com.

SOURCE Centene Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Video: Medtronic Partners with Patient Advocacy Gr...
S
Cornerstone Therapeutics Provides a Response to FD...